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Preliminary Results

Introduction

Discussion & Conclusions

The semenogelin proteins (SEMG1 and SEMG2) make up nearly
50% of the total protein in semen, and protect spermatozoa by
undergoing non-covalent crosslinking to form the coagulum after
ejaculation.
Figure 3: Diagram of fragments chosen to be amplified and tested for expression.

Semenogelin can also be used to detect the presence of seminal
fluid in suspected cases of sexual assault. By optimizing methods
for creating peptide fragments of the semenogelin proteins, we can
create novel antibodies for improved detection of human semen.
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Figure 4: Agarose gel of amplified human SEMG1
segment IIa in quadruplicate samples (A-D),
stained with ethidum bromide.
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Figure 5: Patch plate of human SEMG1 IIIa
fragments cloned into a transfer vector

• With fragments confirmed in a transfer vector, a
double digest using EcoR1 and HindIII will allow for
the movement into an expression vector
• Lower bands are the confirmed isolated fragments
and can be purified via gel purification
• Segments again transferred to a mammalian
expression vector to allow to the production of
semenogelin protein
• Fragments cultured in HEK-293T cells and expression
monitored using and SDS-Page gel and western blot
assays
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Figure 6: Agarose gel of double
digested human SEMG1 fragments
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Figure 7: Patch plate of human
SEMG1 IIIa fragments cloned
into pScript expression vector.

Figure 8: Photo of Human 293T Cells.
Photo courtesy of Jennifer Vill (JensenSeaman lab).
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Future Directions

• Repeat processes with Human Semenogelin 2
• Double check all sequences for error
• Optimize transfection process to get proper expression
of protein (using full length SEMG1 gene)
• Test commercially available antibodies for their ability
to detect the semenogelin fragments and whole
SEMG1c ene
• Determine an appropriate method for the optimized
creation of antibodies and test their ability of
detection
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Each segment was amplified and worked in parallel
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This abundance makes the semenogelins effective markers for the
detection of semen even when whole spermatozoa are not present.
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Figure 1: Interactions between the structural SEMG1 and SEMG2 proteins (secreted by
the seminal vesicles) and the enzymes TGM4, ACPP, and KLK3 (secreted by the prostate).

Four total fragments were chosen to be amplified and tested. Each segment was
amplified from the start codon through the end of a specific segment of the gene.
Chosen amplicons consisted of the start codon through the Ia, IIa, and IIIa
segments, as well as the full length semenogelin 1 gene.

So far we have been able to successfully:
• Amplify human Semenogelin 1 fragments Ia, IIa, IIIa
• Purify and digest amplified fragments
• Optimize amplification and ensure complete digest
• Move amplicons into transfer vector and confirm via
sequencing
- Create stocks of culture for storage
• Digest fragments out of transfer vector
• Cloned all fragments into the pScript expression vector
- Observed plate growth
- Confirmed via sequencing
The work done so far has created an optimized method
for the consistent amplification of the Semenogelin 1
fragments and a method to ensure complete digestion of
the fragments before transformation. The transfer vector
has also been very successful in accepting the fragments
for large scale growth and further transformations.
• Methods are equally useful for Semenogelin 2
Transfected segments into human 293T cells to test
expression with no observable protein production
• Protocols and antibodies can be altered to try and
optimize the process

Figure 9: Expected protein expression
results of SDS-PAGE gel, by Hannah
Johnstonbaugh.
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